US equities |
META $623.08 ▼-1.19% TSLA $406.76 ▲+3.87% MU $932.88 ▲+3.23% NVDA $217.79 ▲+0.83% SPCX $150.05 ▲+2.14% AMD $559.43 ▲+5.30% SNDK $1,303.53 ▲+3.82% INTC $93.72 ▲+3.60%
FinancialContent

Articles published by La Jolla Pharmaceutical Company

News headline image
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
From La Jolla Pharmaceutical Company
Via Business Wire
News headline image
Innoviva to Acquire La Jolla Pharmaceutical Company
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers INVA LJPC
News headline image
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
News headline image
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
News headline image
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
News headline image
Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
News headline image
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
News headline image
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC